However, mutations in BRAF can independently lead to uncontrolled cellular proliferation and cell survival through ERK signaling, and have been detected in melanoma (50–60%), colorectal cancer (10%), thyroid cancer (30–50%), serous ovarian cancer (30%), and non-small-cell lung cancer (NSCLC; 3%), amongst others [2,3]. Here, BRAF is linked to non-small cell lung carcinoma.